Last 12 months
Inside the activity.
5 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 4 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2023 Filed Mar 21, 2023 23:54 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 205,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001437749-23-007440 · rdgdoc.xml · derivative · entry 6 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2033-03-16 F2 · derivative.exercise_date: The shares subject to this stock option shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:54 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007440 · rdgdoc.xml · nonDerivative · entry 3 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,788 F3 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of February 2, 2023, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:54 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
GrantCommon Stock | 54,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007440 · rdgdoc.xml · nonDerivative · entry 2 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,788 F1 · shares: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:54 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007440 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,631 F1 · shares: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:53 UTC |
Cummings James F.Chief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 410,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001437749-23-007439 · rdgdoc.xml · derivative · entry 5 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2033-03-16 F4 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on February 2, 2024, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on February 2, 2027. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:53 UTC |
Cummings James F.Chief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 205,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001437749-23-007439 · rdgdoc.xml · derivative · entry 4 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2033-03-16 F2 · derivative.exercise_date: The shares subject to this stock option shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:53 UTC |
Cummings James F.Chief Medical Officer
|
GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007439 · rdgdoc.xml · nonDerivative · entry 3 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,100 F3 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of February 2, 2023, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:53 UTC |
Cummings James F.Chief Medical Officer
|
GrantCommon Stock | 59,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007439 · rdgdoc.xml · nonDerivative · entry 2 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,100 F1 · shares: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:53 UTC |
Cummings James F.Chief Medical Officer
|
GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007439 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,750 F1 · shares: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed May 12, 2023 00:33 UTC Amendment |
Lee Phillip EChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 205,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001437749-23-014018 · rdgdoc.xml · derivative · entry 3 Lee Phillip E · CIK 0001959565 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2033-03-16 F2 · shares: This amendment is also being filed to remove the grant of 410,000 shares of common stock in the form of stock options incorrectly reported on the Form 4 filed on March 21, 2023, due to an administrative error. Table II is fully restated to reflect the correct number of stock options held by the Reporting Person on March 17, 2023 to be 205,000, and to remove footnote 4 previously included on the Form 4 filed on March 21, 2023, due to an administrative error. This amendment does not otherwise modify any transaction details that were previously reported in Table II on the Form 4. F3 · derivative.exercise_date: The shares subject to this stock option shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed May 12, 2023 00:33 UTC Amendment |
Lee Phillip EChief Financial Officer
|
GrantCommon Stock | 56,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-014018 · rdgdoc.xml · nonDerivative · entry 2 Lee Phillip E · CIK 0001959565 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,402 F1 · shares: This amendment is being filed to remove the grant of 90,000 shares of common stock that appeared in Table I, and to remove footnote 3 previously included on the Form 4 filed on March 21, 2023, due to an administrative error. Table I is fully restated to reflect the correct number of common stock held by the Reporting Person on March 17, 2023 to be 170,402. This amendment does not otherwise modify any transaction details that were previously reported in Table I on the Form 4. Read SEC document |
| March 17, 2023 Filed May 12, 2023 00:33 UTC Amendment |
Lee Phillip EChief Financial Officer
|
GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-014018 · rdgdoc.xml · nonDerivative · entry 1 Lee Phillip E · CIK 0001959565 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,750 F1 · shares: This amendment is being filed to remove the grant of 90,000 shares of common stock that appeared in Table I, and to remove footnote 3 previously included on the Form 4 filed on March 21, 2023, due to an administrative error. Table I is fully restated to reflect the correct number of common stock held by the Reporting Person on March 17, 2023 to be 170,402. This amendment does not otherwise modify any transaction details that were previously reported in Table I on the Form 4. Read SEC document |
| December 28, 2022 Filed Dec 28, 2022 22:25 UTC |
Watson W. MarkDirector
|
PurchaseCommon Stock | 20,000 | $0.76 | $15,140.00 |
DisclosureSEC source: 0001437749-22-029843 · rdgdoc.xml · nonDerivative · entry 1 Watson W. Mark · CIK 0001612372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| December 16, 2022 Filed Dec 31, 2022 01:21 UTC |
Lee Phillip EChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 412,500 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001437749-22-029969 · rdgdoc.xml · derivative · entry 2 Lee Phillip E · CIK 0001959565 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,500 Underlying: Common Stock · 412,500 shares Expires 2032-12-15 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on December 15,2023, the first anniversary of the Start Date, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on December 16, 2026. Read SEC document |
| December 16, 2022 Filed Dec 31, 2022 01:21 UTC |
Lee Phillip EChief Financial Officer
|
GrantCommon Stock | 68,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-029969 · rdgdoc.xml · nonDerivative · entry 1 Lee Phillip E · CIK 0001959565 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,750 F1 · shares: Grant of shares upon vesting of restricted stock units ("RSUs"). The RSUs vest as to 25% of the shares underlying the award on each anniversary of December 15, 2022 (the "Start Date"), so that the RSUs would be fully vested on the fourth anniversary of the Start Date. Read SEC document |
| August 25, 2022 Filed Aug 25, 2022 21:06 UTC |
HERON ELAINE JDirector
|
GrantStock Option (right to buy) · Derivative | 88,448 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0001437749-22-021354 · rdgdoc.xml · derivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,448 Underlying: Common Stock · 88,448 shares Expires 2032-08-24 F2 · derivative.exercise_date: The shares subject to this option shall vest annually over three years from the vesting commencement date of August 25, 2022, the date of the grantee's appointment as a director of Vaxart, Inc. Read SEC document |
| August 25, 2022 Filed Aug 25, 2022 21:06 UTC |
HERON ELAINE JDirector
|
GrantCommon Stock | 14,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-021354 · rdgdoc.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,644 F1 · shares: Grant of shares upon vesting of restricted stock units. One third of the shares underlying the award shall vest on each anniversary of the grant date, so that the restricted stock units would be fully vested on the third anniversary of the grant date. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 19:46 UTC |
Yedid Robert A.Director
|
GiftCommon Stock | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-021394 · rdgdoc.xml · nonDerivative · entry 3 Yedid Robert A. · CIK 0001792558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,115 F2 · price: The shares were gifted to a non-immediate family member who does not share the same household as the Reporting Person. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 19:46 UTC |
Yedid Robert A.Director
|
GiftCommon Stock | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-021394 · rdgdoc.xml · nonDerivative · entry 2 Yedid Robert A. · CIK 0001792558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,115 F2 · price: The shares were gifted to a non-immediate family member who does not share the same household as the Reporting Person. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 19:46 UTC |
Yedid Robert A.Director
|
GiftCommon Stock | 18,240 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-021394 · rdgdoc.xml · nonDerivative · entry 1 Yedid Robert A. · CIK 0001792558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,115 F1 · price: The shares were gifted to a registered charitable organization. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 22:06 UTC |
Yedid Robert A.Director
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001437749-22-021144 · rdgdoc.xml · derivative · entry 5 Yedid Robert A. · CIK 0001792558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,700 Underlying: Common Stock · 8,000 shares Expires 2030-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 22:06 UTC |
Yedid Robert A.Director
|
Exercise / conversionStock Option (right to buy) · Derivative | 18,240 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001437749-22-021144 · rdgdoc.xml · derivative · entry 4 Yedid Robert A. · CIK 0001792558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,240 Underlying: Common Stock · 18,240 shares Expires 2029-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option vest annually over three years from the vesting commencement date of October 25, 2019, the date of the grantee's appointment as a director of Vaxart, Inc. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 22:06 UTC |
Yedid Robert A.Director
|
Exercise / conversionCommon Stock | 8,000 | $2.39 | $19,120.00 |
DisclosureSEC source: 0001437749-22-021144 · rdgdoc.xml · nonDerivative · entry 2 Yedid Robert A. · CIK 0001792558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 22:06 UTC |
Yedid Robert A.Director
|
Exercise / conversionCommon Stock | 18,240 | $0.31 | $5,654.40 |
DisclosureSEC source: 0001437749-22-021144 · rdgdoc.xml · nonDerivative · entry 1 Yedid Robert A. · CIK 0001792558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:31 UTC |
Finney Michael J.Director
|
GrantStock Option (right to buy) · Derivative | 44,224 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001437749-22-019440 · rdgdoc.xml · derivative · entry 2 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,224 Underlying: Common Stock · 44,224 shares Expires 2032-08-03 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:31 UTC |
Finney Michael J.Director
|
GrantCommon Stock | 7,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019440 · rdgdoc.xml · nonDerivative · entry 1 Finney Michael J. · CIK 0001650978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 663,465 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:39 UTC |
Watson W. MarkDirector
|
GrantStock Option (right to buy) · Derivative | 88,448 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001437749-22-019446 · rdgdoc.xml · derivative · entry 2 Watson W. Mark · CIK 0001612372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,448 Underlying: Common Stock · 88,448 shares Expires 2032-08-03 F2 · derivative.exercise_date: The shares subject to this option shall vest annually over three years from the vesting commencement date of August 4, 2022, the date of the grantee's appointment as a director of Vaxart, Inc. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:39 UTC |
Watson W. MarkDirector
|
GrantCommon Stock | 14,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019446 · rdgdoc.xml · nonDerivative · entry 1 Watson W. Mark · CIK 0001612372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,750 F1 · shares: Grant of shares upon vesting of restricted stock units. One third of the shares underlying the award shall vest on each anniversary of the grant date, so that the restricted stock units would be fully vested on the third anniversary of the grant date. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:36 UTC |
Yedid Robert A.Director
|
GrantStock Option (right to buy) · Derivative | 44,224 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001437749-22-019444 · rdgdoc.xml · derivative · entry 3 Yedid Robert A. · CIK 0001792558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,224 Underlying: Common Stock · 44,224 shares Expires 2032-08-03 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:36 UTC |
Yedid Robert A.Director
|
GrantCommon Stock | 7,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019444 · rdgdoc.xml · nonDerivative · entry 1 Yedid Robert A. · CIK 0001792558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,115 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:34 UTC |
Wheadon David E.Director
|
GrantStock Option (right to buy) · Derivative | 44,224 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001437749-22-019442 · rdgdoc.xml · derivative · entry 2 Wheadon David E. · CIK 0001789507 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,224 Underlying: Common Stock · 44,224 shares Expires 2032-08-03 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:34 UTC |
Wheadon David E.Director
|
GrantCommon Stock | 7,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019442 · rdgdoc.xml · nonDerivative · entry 1 Wheadon David E. · CIK 0001789507 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,375 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:26 UTC |
Davis Todd CDirector
|
GrantStock Option (right to buy) · Derivative | 44,224 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001437749-22-019437 · rdgdoc.xml · derivative · entry 2 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,224 Underlying: Common Stock · 44,224 shares Expires 2032-08-03 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:26 UTC |
Davis Todd CDirector
|
GrantCommon Stock | 7,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019437 · rdgdoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,905 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:22 UTC |
Cherrington Julie MDirector
|
GrantStock Option (right to buy) · Derivative | 37,280 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001437749-22-019435 · rdgdoc.xml · derivative · entry 2 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,280 Underlying: Common Stock · 37,280 shares Expires 2032-08-03 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:22 UTC |
Cherrington Julie MDirector
|
GrantCommon Stock | 6,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019435 · rdgdoc.xml · nonDerivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,217 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 20:32 UTC |
Ahmad FuadInterim CFO
|
PurchaseCommon Stock | 5,000 | $3.22 | $16,100.00 |
DisclosureSEC source: 0001437749-22-015757 · rdgdoc.xml · nonDerivative · entry 1 Ahmad Fuad · CIK 0001379591 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| April 22, 2022 Filed Apr 25, 2022 20:40 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001437749-22-009651 · rdgdoc.xml · derivative · entry 4 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,061 Underlying: Common Stock · 40,000 shares Expires 2029-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests over a four-year period, with 25% of the shares subject to the stock option vesting on the first anniversary of the vesting commencement date of May 10, 2019, and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| April 22, 2022 Filed Apr 25, 2022 20:40 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
Exercise / conversionCommon Stock | 40,000 | $0.77 | $30,800.00 |
DisclosureSEC source: 0001437749-22-009651 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:24 UTC |
Cummings James F.Chief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 262,500 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001437749-22-007741 · rdgdoc.xml · derivative · entry 2 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 262,500 shares Expires 2032-03-27 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 28, 2023, the first anniversary of the date that the grant was approved by the board of directors, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 28, 2026. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:24 UTC |
Cummings James F.Chief Medical Officer
|
GrantCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-007741 · rdgdoc.xml · nonDerivative · entry 1 Cummings James F. · CIK 0001886760 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 F1 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the grant date, so that the restricted stock units would be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:20 UTC |
Floroiu Cezar AndreiDirector · President, Chief Exec Officer
|
GrantStock Option (right to buy) · Derivative | 550,000 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001437749-22-007739 · rdgdoc.xml · derivative · entry 2 Floroiu Cezar Andrei · CIK 0001808794 · Director · President, Chief Exec Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2032-03-27 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 28, 2023, the first anniversary of the date that the grant was approved by the board of directors, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 28, 2026. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:20 UTC |
Floroiu Cezar AndreiDirector · President, Chief Exec Officer
|
GrantCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-007739 · rdgdoc.xml · nonDerivative · entry 1 Floroiu Cezar Andrei · CIK 0001808794 · Director · President, Chief Exec Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 F1 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the grant date, so that the restricted stock units would be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:19 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 262,500 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001437749-22-007738 · rdgdoc.xml · derivative · entry 4 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 262,500 shares Expires 2032-03-27 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 28, 2023, the first anniversary of the date that the grant was approved by the board of directors, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 28, 2026. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:19 UTC |
Tucker SeanSVP, Chief Scientific Officer
|
GrantCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-007738 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,631 F1 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the grant date, so that the restricted stock units would be fully vested on the fourth anniversary of the grant date. Read SEC document |
| February 15, 2022 Filed Feb 22, 2022 21:04 UTC |
Berg Edward BSVP, General Counsel
|
GrantStock Option (right to buy) · Derivative | 285,000 | $0.00 Strike: $5.07 | $0.00 |
DisclosureSEC source: 0001437749-22-004055 · rdgdoc.xml · derivative · entry 1 Berg Edward B · CIK 0001912178 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Stock · 285,000 shares Expires 2032-02-14 F1 · date: Reported late due to administrative error. F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on February 14, 2023, the first anniversary of the date that the grant was approved by the board of directors, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on February 14, 2026. Read SEC document |
| January 10, 2022 Filed Oct 7, 2022 21:32 UTC |
Yedid Robert A.Director
|
SaleCommon Stock | 1,500 | $6.01 | $9,015.15 |
DisclosureSEC source: 0001437749-22-023849 · rdgdoc.xml · nonDerivative · entry 1 Yedid Robert A. · CIK 0001792558 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · shares: Due to an administrative error, the Reporting Person inadvertently failed to report the sale of these shares, which were held by the Reporting Person's spouse, and, therefore, the total amount of securities beneficially owned by the Reporting Person in column 5 of Table I of Forms 4 filed on August 8, 2022, and August 22, 2022, is overstated by the amount of these shares. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:07 UTC |
Davis Todd CDirector
|
GiftCommon Stock | 1,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-029223 · rdgdoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,530 F1 · security: This transaction represents a gift / charitable donation effective December 22, 2021. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 21:05 UTC |
Echerd MargaretSVP, Principal Accntng Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,936 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001437749-21-027623 · rdgdoc.xml · derivative · entry 5 Echerd Margaret · CIK 0001530193 · SVP, Principal Accntng Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,416 Underlying: Common stock · 2,936 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests over a four-year period, with 25% of the shares subject to the stock option vesting on the first anniversary of the vesting commencement date of May 10, 2019, and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 21:05 UTC |
Echerd MargaretSVP, Principal Accntng Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 666 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001437749-21-027623 · rdgdoc.xml · derivative · entry 4 Echerd Margaret · CIK 0001530193 · SVP, Principal Accntng Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Common stock · 666 shares Expires 2028-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests over a four-year period, with 25% of the shares subject to the stock option vesting on the first anniversary of the vesting commencement date of April 9, 2018, and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.